Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(2.61) per share which missed the analyst consensus estimate of $(2.10) by 24.29 percent. This is a 8.75 percent decrease over losses of $(2.40) per share from the same period last year.
Chemours Q3 Adj. EPS $1.24 Beats $1.07 Estimate, Sales $1.78B Beat $1.68B Estimate
Chemours (NYSE:CC) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.07 by 15.89 percent. This is a 2.36 percent decrease over earnings of $1.27 per share from the same period
